Targeted proteomic profiling of cardiogenic shock in the cardiac intensive care unit
European Heart Journal: Acute Cardiovascular Care, 2024
Patel S., Lopes M., Morrow D., Bellavia A., Bhatt A., Butler K., D’Antonio J., Dunn M., Fagundes A., Jarolim P., Marin E., Morton L., Olenchock B., Senman B., da Silva D., Varshney A., Bohula E., Berg D.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
CVD | Patient Stratification | Blood |  Olink Target 96 |
Abstract
Aims
We sought to characterize circulating protein biomarkers associated with cardiogenic shock (CS) using highly multiplex proteomic profiling.
Methods and results
This analysis employed a cross-sectional case–control study design using a biorepository of patients admitted to a cardiac intensive care unit between 2017 and 2020. Cases were patients adjudicated to have CS, and controls were those presenting for cardiac critical care without shock, including subsets of patients with isolated hypotension or heart failure (HF). The Olink platform was used to analyse 359 biomarkers with Bonferroni correction. The analysis included 239 patients presenting for cardiac critical care (69 cases with CS, 170 non-shock controls). A total of 63 biomarkers (17.7%) were significantly associated with CS after Bonferroni correction compared with all controls. Of these, nine biomarkers remained significantly associated with CS when separately cross-validated in subsets of controls presenting with isolated hypotension and HF: cathepsin D, fibroblast growth factor (FGF)-21 and -23, growth differentiation factor (GDF)-15, insulin-like growth factor-binding protein-1, N-terminal pro-B-type natriuretic peptide, osteopontin, oncostatin-M-specific receptor subunit beta (OSMR), and soluble ST2 protein (sST2). Four biomarkers were identified as providing complementary information for CS diagnosis with development of a multi-marker model: sST2, FGF-23, CTSD, and GDF-15.
Conclusion
In this pilot study of targeted proteomic profiling in CS, we identified nine biomarkers significantly associated with CS when cross-validated against non-shock controls including those with HF or isolated hypotension, illustrating the potential application of a targeted proteomic approach to identify novel candidates that may support the diagnosis of CS.